101. Long-term anti-TNF therapy and the risk of serious infections in a cohort of patients with rheumatoid arthritis: Comparison of adalimumab, etanercept and infliximab in the GISEA registry
- Author
-
Atzeni, F, Sarzi Puttini, P, Botsios, C, Carletto, A, Cipriani, P, Favalli, Eg, Frati, E, Foschi, V, Gasparini, S, Giardina, A, Gremese, E, Iannone, F, Sebastiani, M, Ziglioli, T, Biasi, D, Ferri, C, Galeazzi, M, Gerli, Roberto, Giacomelli, R, Gorla, R, Govoni, M, Lapadula, G, Marchesoni, A, Salaffi, F, Punzi, L, Triolo, G, Ferraccioli, G, on behalf of GISEA, Atzeni F, Sarzi-Puttini P, Botsios C, Carletto A, Cipriani P, Favalli EG, Frati E, Foschi V, Gasparini S, Giardina A, Gremese E, Iannone F, Sebastiani M, Ziglioli T, Biasi D, Ferri C, Galeazzi M, Gerli R, Giacomelli R, Gorla R, Govoni M, Lapadula G, Marchesoni A, Salaffi F, Punzi L, Triolo G, and Ferraccioli G
- Subjects
Male ,rheumatoid arthritis ,Arthritis ,Receptors, Tumor Necrosis Factor ,Etanercept ,Arthritis, Rheumatoid ,Adalimumab ,Adult ,Aged ,Antibodies, Monoclonal ,Antibodies, Monoclonal, Humanized ,Antirheumatic Agents ,Female ,Humans ,Immunoglobulin G ,Incidence ,Infection ,Infliximab ,Middle Aged ,Registries ,Tumor Necrosis Factors ,Rheumatoid ,adalimumab ,Monoclonal ,Receptors ,Immunology and Allergy ,infections ,Humanized ,Anti-TNF agents ,GISEA register ,Infections ,Predictive factors ,Incidence (epidemiology) ,Rheumatoid arthritis ,Cohort ,medicine.drug ,anti-TNF ,serious infections ,medicine.medical_specialty ,anti-TNF therapy ,etanercept ,infliximab ,Immunology ,Infections, rheumatoid arthritis, anti-TNF therapy ,Antibodies ,Internal medicine ,medicine ,business.industry ,medicine.disease ,Concomitant ,Tumor Necrosis Factor Inhibitors ,business ,Tumor Necrosis Factor - Abstract
Objective: To evaluate the risk of serious infections (SIs) in RA patients receiving anti-TNF therapy on the basis of the data included in the GISEA register. METHODS: The study involved 2769 adult patients with long-standing RA (mean age 53.2±13.4years; mean disease duration 9.0±8.3years) enrolled in the GISEA register, who had been treated for at least 6months with TNF inhibitors or had discontinued therapy due to SI: 837 (30%) treated with infliximab (IFN), 802 (29%) with adalimumab (ADA), and 1130 (41%) with etanercept (ETN). RESULTS: 176 patients had experienced at least one of the 226 Sis during the 9years of treatment with an anti-TNF agent, an overall incidence of 31.8/1000 patient-years (95% CI 25.2-38.3): 23.7/1000 patient-years (95% CI 13.1-34.2) on ADA; 12.8/1000 patient-years (95% CI 6.3-19.4) on ETN and 65.1/1000 patient-years (95% CI 48.4-81.8) on IFN. The risk was higher in the first than in the second year of treatment, but this difference was not statistically significant (p=0.08) (38.9% of the SIs were recorded in the first 12months of treatment). The risk of SI was significantly different among the three treatment groups (p
- Published
- 2012